aMoon and Luma Group led a $93m Series B round in Character Biosciences.

aMoon, a venture capital, and Luma Group, a private equity firm, led a $93m Series B round in Character Biosciences, a biotechnology firm, with participation from Bausch + Lomb and Jefferson Life Sciences, Endeavors, Catalio Capital Management, S32, and KdT Ventures. “Millions of patients suffering from degenerative eye diseases lack effective treatments that delay disease progression. By identifying the genetic modifiers of their disease progression, we can develop therapeutics to more precisely target the root causes of disease and improve clinical translation. This funding allows us to advance our lead programs into first-in-human trials, with the goal of bringing new therapies to patients who urgently need them,” Cheng Zhang, Character Biosciences CEO & Co-Founder.